Skip to main content

Posts

Showing posts from December 17, 2025

Efficacy of ProC6C-AlOH/Matrix-M against #Plasmodium falciparum #infection and #mosquito #transmission: a phase 2, randomised, controlled human malaria infection study

  Summary Background An investigational multistage malaria vaccine, ProC6C, based on distinct Plasmodium falciparum epitopes from the sporozoite stage (P falciparum circumsporozoite protein [PfCSP]) and the transmission stages (Pfs230 and Pfs48/45), adsorbed to aluminium hydroxide (AlOH) and adjuvanted with Matrix-M adjuvant (ProC6C-AlOH/MM), has previously shown safety and immunogenicity in phase 1 studies. We aimed to study vaccine efficacy, safety, and immunogenicity in African adults with lifelong malaria exposure. Methods This randomised controlled double-blind vaccination and controlled human malaria infection (CHMI) study was conducted in Sotuba, a peri-urban setting in Mali . Healthy adults (aged 18–50 years), who were malaria experienced and met eligibility criteria, were randomly assigned (1:1) to receive three intramuscular injections of ProC6C-AlOH/MM (100 μg ProC6C and 50 μg Matrix-M adjuvant) or Verorab rabies vaccine (control) 4 weeks apart. Randomisation was done in...

Immunological and virological #questions for #H5N1 #pandemic emergence

  Abstract Zoonotic spillover of influenza A viruses into humans has repeatedly triggered pandemics throughout history. Since their emergence in the 1990s, H5N1 influenza viruses have significantly expanded their geographical range and host species , raising global concern about the potential for sustained human-to-human transmission . In this review , we examine the virological characteristics of currently circulating H5N1 strains, key molecular barriers limiting their spread among humans, and critical areas of future research to mitigate the ongoing H5N1 panzootic and prevent future pandemics. Source:  Link:  https://academic.oup.com/immunohorizons/article/9/SI/vlaf062/8381786 ____

Mass #mortality at #penguin mega-colonies due to avian cholera confounds #H5N1 HPAIV #surveillance in #Antarctica

  Abstract In the austral summer 2023/2024, H5N1 high pathogenicity avian influenza virus (HPAIV) was reported for the first time in Antarctica . Concerns of HPAIV causing high mortality of seabirds and mammals prompted immediate efforts to track its spread and impact on endemic wildlife. In March 2024, we visited the Danger Islands archipelago , that hosts two mega-colonies of AdĂ©lie penguins , and observed an unusual mortality estimated in thousands of AdĂ©lie penguins and other species . Swabs and tissues were collected for molecular detection of infectious agents from 49 carcasses, and additional tissues for histology from a selection of 9 carcasses. We unexpectedly detected Pasteurella multocida DNA in 46 of 49 individuals, and diagnosed avian cholera , and not HPAI , as the cause of death of most of these animals. By metagenomics, we retrieved the genomic sequences of the Pasteurella multocida strain which caused the epizootic, and the phylogenetic analysis showed a close rela...

New {seasonal} #influenza {#H3N2} #variant is surging, but #vaccination still our best bet: #WHO (#UN, Dec. 17 '25)

  16 December 2025  Amid an early start to the Northern Hemisphere influenza season a new variant of the virus is rapidly gaining ground - but vaccination remains the “most effective defence”, the UN health agency said on Tuesday. Influenza and other respiratory viruses are surging, Dr Wenqing Zhang, Unit Head for Global Respiratory Threats at the Department of Epidemic and Pandemic Threats Management of the World Health Organization (WHO) told reporters in Geneva, and this year is marked by “the emergence and the rapid expansion of a new AH3N2 virus subclade ”. The new variant - called J.2.4.1 or subclade K - was first noted in August in Australia and New Zealand and has since been detected in over 30 countries, she said. “Current epidemiological data do not indicate an increase in disease severity , although this genetic shift makes a notable evolution in the virus,” Dr Zhang said. Influenza viruses are constantly evolving , she explained, which is why the influenza vaccine ...